Key facts
- Spotlight Pathology’s last known valuation is $2.3M (Mar 2022).
- It has raised $3.1M; the latest was Seed Round ($2.6M) in Mar 2026.
- Notable investors include Innovate UK, UK Innovation & Science Seed Fund, Deepbridge Capital, River Capital (Liverpool ), AXM Venture Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Spotlight Pathology
- ·The full record, as it builds
Funding rounds
No funding rounds for Spotlight Pathology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Spotlight Pathology
Developer of a medical diagnostic platform designed to integrate bioinformatics and genomics to detect blood cancer. The company's platform incorporates artificial intelligence for the analysis of digital histopathology image data and multiplex immunofluorescence image data for disease outcome prediction, enabling doctors to facilitate the detection and diagnosis of blood cancers at an early stage.
- Sector
- Healthcare
- HQ
- Daresbury, United Kingdom
- Founded
- 2020
- Employees
- 6
- Website
- spotlightpathology.com/
- Ownership
- Privately Held (backing)
Spotlight Pathology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spotlight Pathology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spotlight Pathology in its N-PORT filings yet. We sweep new filings monthly.